Non-immunologic intervention in chronic allograft nephropathy

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Arias, Manuel ^a   Fernández Fresnedo, Gema ^a   Rodrigo, Emilio ^a   Ruiz, Juan Carlos ^a   González Cotorruelo, Julio ^a   Gómez Alamillo, Carlos ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Chronic allograft nephropathy; Progression renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCINEURIN INHIBITOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANEMIA; CHRONIC ALLOGRAFT NEPHROPATHY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRAFT FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN URINE LEVEL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; ALLOTRANSPLANTATION; ARTICLE; BLOOD; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; ANEMIA; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; CREATININE; DISEASE PROGRESSION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERLIPIDEMIAS; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748311903     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09922.x     Document Type: Conference Paper

References (32)

1. MEIER-KRIESCHE HU, SCHOLD JD, SRINIVAS TR, KAPLAN B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378-383, 2004
2. NANKIVELL BJ, BORROWS RJ, FUNG CL, et al: The natural history of chronic allograft nephropathy. N Engl J Med 349:2326-2333, 2003
3. HERNANDEZ-FUENTES MP, LECHLER RI: Chronic graft loss. Immunological and non-immunological factors. Contrib Nephrol 146:54-64, 2005
4. PALLARDO MATEU LM, SANCHO CALABUIG A, CAPDEVILA PLAZA L, FRANCO ESTEVE A: Acute rejection and late renal transplant failure: Risk factors and prognosis. Nephrol Dial Transplant 19(Suppl 3):iii38-iii42, 2004
5. OPPENHEIMER F, ALJAMA P, ASENSIO PEINADO C, et al: The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 19(Suppl 3):iii11-iii15, 2004
6. RODRIGO E, RUIZ JC, PIÑERA C, et al: Creatinine reduction ratio on post-transplant day two as criterion in defining delayed graft function. Am J Transplant 4:1163-1169, 2004
7. WOO YM, PEREIRA BJ, GILL JS: Chronic kidney disease progression in native and transplant kidneys. Curr Opin Nephrol Hypertens 13:607-611, 2004
8. BURTON C, HARRIS KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27:765-775, 1996
9. JAFAR TH, STARK PC, SCHMID CH, et al: AIPRD Study Group. Angiotensin-converting enzyme inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001
10. FERNÁNDEZ-FRESNEDO G, PLAZA JJ, SANCHEZ-PLUMED J, et al: Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplan 19(Suppl 3):47-51, 2004
11. FERNÁNDEZ-FRESNEDO G, ESCALLADA R, RODRIGO E, et al: The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 73:1345-1348, 2002
12. PARVING HH, ANDERSEN AR, SMIDT UM, SNENDSEN PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179, 1983
13. MARCANTONI C, JAFAR TH, OLDRIZZI L, et al: The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int 57(Suppl 75):44-48, 2000
14. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
15. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
16. REMUZZI G, PERICO N: Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens 11:1-10, 2002
17. ZALZMAN JS, NASH M, CHUI R, PRASAD R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 19:940-944, 2004
18. ARTZ MA, HILBRANDS LB, BORN G, et al: Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 19:2852-2857, 2004
19. IÑIGO P, CAMPISTOL JM, CARACHO R, et al: Renoprotective effects of losartan in renal transplant recipients. Nephrol Clin Pract 95:c84-c90, 2003
20. FRIED LF, ORCHARD TJ, KASISKE BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
21. EPSTEIN M, CAMPESE VM: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 45:2-14, 2005
22. BLANCO S, VAQUERO M, GOMEZ-GUERRERO C, et al: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity and mild hypertension. Am J Hypertens 18:557-565, 2005
23. JI P, SI MS, PODNOS Y, et al: Prevention of chronic rejection by pravastatin in a rat kidney transplant model. Transplantation 27:821-827, 2002
24. DEL CASTILLO D, CRUZADO JM, DIAZ JM, et al: The effects of hyperlipidemia on graft and patients outcome in renal transplantation. Nephrol Dial Transplant 19(Suppl 3):iii67-iii71, 2004
25. FELLSTROM B, HOLDAAS H, JARDINE AG, et al: Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation trial. Transplantation 79:205-212, 2005
26. HÖRL WH: The clinical consequences of secondary hyperparathyroidism: Focus on clinical outcomes. Nephrol Dial Transplant 19(Suppl 5):2-8, 2004
27. OGATA H, RITZS E, ODÓN G, et al: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959-967, 2003.
28. VANRENTERGHEM Y, PONTICELLI C, MORALES JM, et al: Prevalence and management of anemia in renal transplant recipients: A European survey. Am J Transplant 3:835-845, 2003
29. RIGATTO C, FOLEY R, JEFFERY J, et al: Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14:462-468, 2003
30. KEANE WF, BRENNER BM, DE ZEEUW D, et al: RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63:1499-1507, 2003
31. NORMAN JT, ORPHANIDES C, GARCIA P, FINE LG: Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 7:463-469, 1999
32. BECKER BN, BECKER YT, LEVERSON GE, HEISEY DM: Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 17:1667-1673, 2002